ArticleJournal of the American Heart Association2021
Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
Article in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure.International journal of molecular sciences · 2023Pooled it
- Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial.ESC heart failure · 2022Pooled it
- Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.European heart journal · 2026Trial
- Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction and asymptomatic hypotension: insights from a multicenter observational cohort study.BMC cardiovascular disorders · 2026Observational
- Use of soluble guanylyl cyclase stimulators in heart failure therapy-a mode of action perspective.ESC heart failure · 2026Review
- Cyclic guanosine monophosphate-protein kinase G signaling attenuates aortic valve calcification through ULK1-mediated autophagy.Signal transduction and targeted therapy · 2026Article
- Vericiguat in heart failure with reduced ejection fraction: not vanity, but vindication.ESC heart failure · 2026Article
- Initiation, titration, and safety of vericiguat for treatment of heart failure in United States clinical practice.American heart journal plus : cardiology research and practice · 2026Article
- The DIGIT-HF trial and the Mihai Gheorghiade legacy: time to reconsider cardiac glycosides as effective therapy in HFrEF.Heart failure reviews · 2026Review
- Safety and tolerability of a 5 mg starting dose of vericiguat among patients with heart failure: The VELOCITY study.European journal of heart failure · 2025Article
- Therapeutic Impact of Vericiguat on Ventricular Remodeling in a Pressure-Overload Heart Failure Model.Life (Basel, Switzerland) · 2025Article
- The Role of Vericiguat in Heart Failure Therapy: From Clinical Trials to Clinical Practice.Reviews in cardiovascular medicine · 2025Review
- Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial.European journal of heart failure · 2025Article
- Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings.Frontiers in pharmacology · 2025Article
- Short-term outpatient follow-up of vericiguat treatment in patients hospitalized for heart failure.Frontiers in cardiovascular medicine · 2025Article
- Emerging therapeutic frontiers in hypertension management.Frontiers in cardiovascular medicine · 2025Review
- Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States.Frontiers in cardiovascular medicine · 2025Article
- Clinical profile, associated events and safety of vericiguat in a real-world cohort: The VERITA study.ESC heart failure · 2024Observational
- Characterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China.Reviews in cardiovascular medicine · 2024Article
- Vericiguat in heart failure with reduced ejection fraction: hope or solid reality?Heart failure reviews · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 10 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Although safety and tolerability of vericiguat were established in the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial in patients with heart failure with reduced ejection fraction, some subgroups may be more susceptible to symptomatic hypotension, such as older patients, those with lower baseline systolic blood pressure (SBP), or those concurrently taking angiotensin receptor neprilysin inhibitors. We described the SBP trajectories over time and compared the occurrence of symptomatic hypotension or syncope by treatment arm in potentially vulnerable subgroups in VICTORIA. We also evaluated the relation between the efficacy of vericiguat and baseline SBP. Methods and Results Among patients receiving at least 1 dose of the study drug (n=5034), potentially vulnerable subgroups were those >75 years old (n=1395), those with baseline SBP 100-110 mm Hg (n=1344), and those taking angiotensin receptor neprilysin inhibitors (n=730). SBP trajectory was plotted as mean change from baseline over time. The treatment effect on time to symptomatic hypotension or syncope was evaluated overall and by subgroup, and the primary efficacy composite outcome (heart failure hospitalization or cardiovascular death) across baseline SBP was examined using Cox proportional hazards models. SBP trajectories showed a small initial decline in SBP with vericiguat in those >75 years old (versus younger patients), as well as those receiving angiotensin receptor neprilysin inhibitors (versus none), with SBP returning to baseline thereafter. Patients with SBP <110 mm Hg at baseline showed a trend to increasing SBP over time, which was similar in both treatment arms. Safety event rates were generally low and similar between treatment arms within each subgroup. In Cox proportional hazards analysis, there were similar numbers of safety events with vericiguat versus placebo (adjusted hazard ratio [HR], 1.18; 95% CI, 0.99-1.39;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.